NasdaqGS:XERSPharmaceuticals
Should Xeris Biopharma Holdings (XERS) Be Revalued After Strong Q2 Revenue And Fresh Guidance?
Why Xeris Biopharma Holdings Stock Is Back in Focus After Fresh Guidance
Xeris Biopharma Holdings (XERS) is back on investors’ radar after its latest earnings update, which combined a tighter full year 2026 revenue outlook with strong second quarter performance.
See our latest analysis for Xeris Biopharma Holdings.
The latest guidance and second quarter update have come alongside some renewed interest in Xeris Biopharma’s stock. The share price is at $7.93, with a 1 day share price return of...